WO2001045740A3 - Compositions et procedes de traitement du cancer du sein - Google Patents

Compositions et procedes de traitement du cancer du sein Download PDF

Info

Publication number
WO2001045740A3
WO2001045740A3 PCT/US2000/035315 US0035315W WO0145740A3 WO 2001045740 A3 WO2001045740 A3 WO 2001045740A3 US 0035315 W US0035315 W US 0035315W WO 0145740 A3 WO0145740 A3 WO 0145740A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
present
subjects
methods
compositions
Prior art date
Application number
PCT/US2000/035315
Other languages
English (en)
Other versions
WO2001045740A2 (fr
Inventor
Geoffrey Clark
Joanne Zujewski
Original Assignee
Geoffrey Clark
Joanne Zujewski
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geoffrey Clark, Joanne Zujewski, Us Gov Health & Human Serv filed Critical Geoffrey Clark
Priority to AU22928/01A priority Critical patent/AU2292801A/en
Publication of WO2001045740A2 publication Critical patent/WO2001045740A2/fr
Publication of WO2001045740A3 publication Critical patent/WO2001045740A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions et des procédés permettant de traiter et/ou prévenir le cancer. En particulier, la présente invention traite de compositions et de procédés pour traiter et/ou prévenir le cancer du sein. De manière spécifique, l'invention a pour objet une thérapie d'association de médicaments qui agit par synergie pour inhiber la croissance des cellules cancéreuses (par exemple, les cellules du sein). Dans certains modes de réalisation, des agents thérapeutiques sont administrés à des sujets suspectés de présenter un cancer ou prédisposés à cette maladie, ou présentant un cancer récidivant ou qui viennent d'être opérés d'un cancer. L'invention envisage également d'administrer les agents de traitement à des patients présentant un risque de cancer.
PCT/US2000/035315 1999-12-22 2000-12-20 Compositions et procedes de traitement du cancer du sein WO2001045740A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU22928/01A AU2292801A (en) 1999-12-22 2000-12-20 Compositions and methods for treatment of breast cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17192899P 1999-12-22 1999-12-22
US60/171,928 1999-12-22

Publications (2)

Publication Number Publication Date
WO2001045740A2 WO2001045740A2 (fr) 2001-06-28
WO2001045740A3 true WO2001045740A3 (fr) 2002-04-25

Family

ID=22625677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/035315 WO2001045740A2 (fr) 1999-12-22 2000-12-20 Compositions et procedes de traitement du cancer du sein

Country Status (2)

Country Link
AU (1) AU2292801A (fr)
WO (1) WO2001045740A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5491681B2 (ja) * 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
PT2269603E (pt) 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
CN113559222A (zh) * 2021-09-14 2021-10-29 临沧宏胜生物科技开发有限公司 一种抑制乳腺癌细胞转移的中药组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032114A1 (fr) * 1997-12-22 1999-07-01 Schering Corporation Combinaison de composes benzocycloheptapyridines et medicaments antineoplasiques pour le traitement de maladies proliferantes
WO2000025789A1 (fr) * 1998-10-29 2000-05-11 Merck & Co., Inc. Procede pour traiter l'endometriose

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032114A1 (fr) * 1997-12-22 1999-07-01 Schering Corporation Combinaison de composes benzocycloheptapyridines et medicaments antineoplasiques pour le traitement de maladies proliferantes
WO2000025789A1 (fr) * 1998-10-29 2000-05-11 Merck & Co., Inc. Procede pour traiter l'endometriose

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"[New strategies for therapy of breast cancer]. BRUSTKREBS: NEUE THERAPIESTRATEGIEN.", MEDIZINISCHE MONATSSCHRIFT FUR PHARMAZEUTEN, (1999) 22/7 (214-216)., XP000956081 *
MOASSER M M ET AL: "Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 FEB 17) 95 (4) 1369-74., XP002187318 *
RANGANATHAN S R ET AL: "Combined cell cycle and cytotoxic effects of paclitaxel and R115777, a specific inhibitor of p21 ras function and protein farnesylation in human prostate and breast carcinoma cell lines.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), 90th Annual Meeting of the American Association for Cancer Research;Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999, pages 523, XP002145679, ISSN: 0197-016X *
SKRZAT S G ET AL: "Interaction of the farnesyl protein transferase inhibitor (FTI) R115777 with cytotoxic chemotherapeutics in vitro and in vivo.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), 90th Annual Meeting of the American Association for Cancer Research;Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999, pages 523, XP002145678, ISSN: 0197-016X *

Also Published As

Publication number Publication date
AU2292801A (en) 2001-07-03
WO2001045740A2 (fr) 2001-06-28

Similar Documents

Publication Publication Date Title
WO1999046279A3 (fr) INHIBITEURS DE LA 17β-HYDROXYSTEROIDE DESHYDROGENASE DU TYPE 5 ET DU TYPE 3 ET METHODES D'UTILISATION ASSOCIEES
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
WO2004064734A3 (fr) Polytherapies anticancereuses
NO20006604L (no) Fremgangsmåter og transdermale sammensetninger for lindring av smerte
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
WO2004039325A3 (fr) Compositions contenant un inhibiteur de jnk destinees a traiter, prevenir, gerer et/ou modifier la douleur, et leurs methodes d'utilisation
DE69738667D1 (de) Vorbeugung und behandlung von kolonadenom oder kolonmikroadenom mit 6-fluorursodeoxycholsäure
ATE353010T1 (de) Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung
BRPI0517976A (pt) métodos de tratamento
BR9713197A (pt) Meios para tratamento de hipertrofia de próstata e câncer de próstata
WO2001030802A3 (fr) Traitements therapeutiques pour des deficiences en cellules sanguines
WO2001008677A8 (fr) Procedes d'inhibition de l'activite des osteoclastes
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
WO2001045740A3 (fr) Compositions et procedes de traitement du cancer du sein
WO2005009363A3 (fr) Traitements d'etats precancereux et prevention du cancer au moyen de therapies a base de pcdgf
GB0020504D0 (en) Therapeutic method
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
HUP9901505A2 (hu) Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására
Eisbruch et al. The prevention and treatment of radiotherapy-induced xerostomia
Schmoll Risks and benefits of various therapies for cancer anorexia
WO2006014507A3 (fr) Procede pour l'inhibition de la peroxydation lipidique
HUP0101005A2 (hu) Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP